Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call

Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) is set to release its fourth quarter and full year 2021 financial results on March 31, 2022. The company specializes in developing safer prescription drugs through innovative technology platforms, focusing on reducing drug abuse and overdose. Following the earnings release, Ensysce will host a corporate update call on April 6, 2022, at 11:00 a.m. ET. This session will offer insights into the company's progress, with a chance for participant Q&A.

Positive

• Scheduled earnings release for Q4 and full year 2021.
• Innovative drug safety technologies aimed at reducing opioid abuse.
• Corporate update call allowing direct engagement with management.

Negative

• None.

SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced plans to release fourth quarter and full year 2021 financial results after close of market on Thursday, March 31, 2022.

Corporate Update Conference Call

Management will host a corporate update conference call on Wednesday, April 6, 2022, at 11:00 a.m. Eastern time. The call will conclude with Q&A from participants.

Date:	Wednesday, April 6, 2022
Time:	11:00 a.m. Eastern time
Dial-in:	1-877-407-0792
International Dial-in:	1-201-689-8263
Conference Code:	13727989
Webcast:	ENSC Corporate Update Conference Call

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

A playback of the call will be available through May 6, 2022 on Ensysce's Investor Relations website at ir.ensysce.com.

About Ensysce Biosciences

Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is developing next-generation, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs. For more information, please visit www.ensysce.com.

Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/694601/Ensysce-Biosciences-Announces-Fourth-Quarter-and-Full-Year-2021-Earnings-Release-Date-and-Timing-of-Corporate-Update-Call

FAQ

When will Ensysce Biosciences release its fourth quarter and full year 2021 financial results?

Ensysce Biosciences will release its financial results on March 31, 2022.

What is the purpose of the corporate update call on April 6, 2022?

The corporate update call will provide insights into Ensysce's developments and allow for a Q&A session.

What technologies does Ensysce Biosciences use to improve drug safety?

Ensysce utilizes the Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms.

What is the ticker symbol for Ensysce Biosciences?

The ticker symbols for Ensysce are ENSC for NASDAQ and ENSCW for OTC PINK.